Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Comment by futuregainson May 16, 2020 8:44am
119 Views
Post# 31037499

RE:My thinking is that the information must remain serious and

RE:My thinking is that the information must remain serious and Sylvain123 said :Here we're talking about VIDOC-19, its symptoms. We have to stop associating any other disease or hypothesis of its own without it being demonstrated by specialists or reported by Algernon himself. 

I agree with you Sylvain about the link with Inflammatory disease and children which is said to be linked with Covid 19. Algernon hasn't said anything about that. Which kind of makes me feel better about their approach. They are not making unfounded claims to get attention like some other companies at this time. Good for them. However, Sylvain I have to disagree with you about what Algernon has said about Infenprodil. Go to their website and read their corporate presentation. It states amongst other drugs they are studying that Infenprodil is being targeted for IPF, and chronic cough. Covid 19 happened after they got the ball rolling on Infenprodil. Not trying to be argumentative, but they are a drug repurposing company that has been doing this since 2016 under the name Breathtec Biomedical Inc. They changed their name in feb 2019 to Algernon. Their bread and butter is going to be theuraputics for lung diseases, not Covid 19. Maybe they can help with Covid 19, I pray they can. Keep in mind though that they have had a different plan since their inception. 


Bullboard Posts